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The objective of this study was to characterize hepatitis C virus (HCV) genotypes in blood donors from the
Federal District, Central Brazil, and to compare HCV screening by serological assays and reverse transcriptase
polymerase chain reaction (RT-PCR). Plasma samples from 57 individuals with reactive or indeterminate results in
serological anti-HCV screening assays (ELISA or EIA) were tested for HCV RNA by RT-PCR. The results from a
confirmatory LIA serological assay were also evaluated. The 5’ non-coding region of the HCV genome was amplified
from 41 PCR positive samples (71.9%), which were further characterized by nucleotide sequencing analysis. Of
these, 60.9% were of HCV genotype 1 and 39.1% of genotype 3.
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Hepatitis C Virus (HCV) has been classified into six
major genotypes and several subtypes, which may pro-
duce clinically relevant differences in the response to in-
terferon therapy. Infection with genotype 1 is associated
with a poorer response to interferon treatment when com-
pared to infection with other genotypes (Zein 2000).
Genotypes 1, 2, and 3 have a worldwide distribution.
Genotype 4 is more prevalent in North Africa and in the
Middle East, while genotypes 5 and 6 occur more com-
monly in South Africa and Asia, respectively (Zein 2000).
In Brazil, several studies have shown that genotype 1 is
the most prevalent one, followed by genotype 3 (Bassit et
al. 1994, Krug et al. 1996, Martins et al. 1998).
 Molecular and serological detections of HCV play an
important role in the diagnosis of infection, therapeutic
decision-making, and assessment of the virologic re-
sponse to therapy. In addition, it might reduce the fre-
quency of post-transfusion hepatitis (Smith et al. 1995,
Zein 2000, Pawlotsky 2002).
The purpose of the present study was to characterize
HCV genotypes in volunteer blood donors from the Fed-
eral District (Central Brazil) and to compare the results of
routine serological assays with those obtained by HCV
reverse transcriptase polymerase chain reaction (RT-PCR).
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Plasma samples from 57 voluntary blood donors were
obtained between March 2001 and June 2002 at two blood
banks located at the Federal District: the Hemocentro and
the Hemoclínica of the Santa Lúcia Hospital. The Commit-
tee on Research Ethics from the University of Brasília
granted prior approval to this research project.
Serum samples were previously screened using rou-
tine HCV enzyme immunoassays (ELISA – Ortho Diag-
nostics Systems or EIA – Abbott Prism HCV). The results
of these anti-HCV assays were expressed as the optical
densities (OD) of the samples divided by the cut off value
(C). Samples with ratio OD/C < 0.9 were considered non-
reactive, and those with ratio OD/C > 0.9 and < 1.1 were
classified as indeterminate. Samples with ratio OD/C > 1
and < 3 were reactive and those with OD/C > 3 were highly
reactive. All 57 samples were retested by a supplementary
line immunoblot assay (Lia Tek HCV III, Organon-Teknika).
All tests were performed according to the manufacturer’s
instructions.
The 57 samples, all classified as reactive or indetermi-
nate by ELISA, were subjected to RNA extraction using
the QIAmp Viral RNA Kit (Qiagen), according to the
manufacturer’s protocol. Complementary DNA (cDNA)
was synthesized from 2 µl of extracted RNA using 200 U
of M-MuLV RT (Gibco-BRL) plus 0.2 mM each dNTP
(Gibco-BRL), 2 U RNAse inhibitor (Pharmacia Biotech),
and 0.5 µg of random primer. The reaction condition was
42°C for 90 min. The cDNA was used as a template in a
nested PCR amplification by using two primer sets match-
ing a conserved region in the 5’ UTR of the different HCV
genotypes (Ginabreda et al. 1997). One microliter of the
resulting cDNA was used in outer PCR amplification, in a
total volume of 50 µl over 35 cycles, each consisting of
15 s at 94°C, 45 s at 50°C and 1 min at 72°C. A final step (7
min at 72°C) was included after the last cycle. The solu-
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tion was adjusted to a final concentration of 0.25 mM
each dNTP (Gibco-BRL), 1x Taq buffer (Gibco-BRL), 20
nM of each primer, and 2 U Taq polymerase (Gibco-BRL).
From the first round of amplification, 1 µl was re-amplified
with the nested primers in the same conditions. For each
PCR assay, water and an anti-HCV negative sample were
used as negative controls. The amplification gave a 253-
bp product from HCV RNA positive samples.
Nested PCR products were sequenced automatically
by the dideoxynucleotide chain termination method, in a
Megabace System (Amersham-Pharmacia). The homology
among HCV sequences from the Federal District and those
already deposited at GenBank was analyzed using the
BLAST program (available at http://www.ncbi.nih.
nlm.gov).
A data bank was generated and analyzed in EPI-Info,
6.04d, from the Center of Diseases Control and Preven-
tion (CDC). The level of significance of tests (p) was set
at  0.05.
The median age of the 57 blood donors included in
our study was 33.5, ranging from 18 to 57 years old. The
majority of them were men (78%) and first-time donors
(82%). Twenty-two individuals (38.6%) reported risk fac-
tors possibly associated to HCV transmission: intrave-
nous drug use (40.9%), surgery (36.4%), blood transfu-
sion (9.1%), and sexually or parentally transmitted dis-
eases (4.5%).
HCV RNA positivity was found in 41 samples (71.9%).
At a previous study in Central Brazil, Martins et al. (1994)
found a similar frequency (76.6%) of HCV viremia in anti-
HCV positive blood donors. These PCR positive samples
were genotyped by  nucleotide sequences similarity analy-
sis using BLAST. The frequency of genotype 1 was 60.9%
and that of genotype 3 was 39.1%. The 41 PCR positive
samples were subtyped as 1a (34.1%), 1b (26.8%), and 3a
(39.1%).
In the supplementary immunoblot assay, 50.8% (n =
29) were reactive, 17.6% (n = 10) had an indeterminate
result, and 31.6% (n = 18) were non-reactive. Of the 41
PCR positive samples, 65.8% (n = 27) had a reactive, 17.1%
(n = 7) an indeterminate, and 17.1% (n = 7) a non-reactive
result on the immunoblot supplementary assay. For the
16 samples with a negative result on PCR, 68.75% were
also negative, 18.75% were indeterminate, and 12.50% were
positive on immunoblot assay. The correlation between
HCV viremia and positivity by serological assays is shown
in the Table.
Due to the fact that some authors previously reported
a relation between anti HCV ratio > 3 and detectable HCV-
RNA by RT nested PCR (Gretch et al. 1992, Gonçalves et
al. 2000), the 57 samples initially classified as reactive or
indeterminate on the anti-HCV serological assay were fur-
ther divided into two groups: 56.1% (n = 32) had ratio OD/
C > 3 and 43.9% (n = 25) < 3. Among the 32 samples with
OD/C > 3, 93.7% (n = 30)  were positive for HCV RNA by
PCR, whereas the 25 with OD/C < 3 only 44% (n = 11) were
PCR positive. No correlation between anti HCV reactive,
PCR positive samples and ALT levels was observed (p =
0.40) and only four individuals showed elevated levels of
transaminases.
Nowadays, the prevention of transfusion-associated
hepatitis C in Brazil relies on the screening of blood
samples and the prevalence of anti-HCV reactive samples
among blood donors in Brazil was 0.52% in 2001 and 0.48%
in 2002 (http://www.anvisa.gov.br). Nevertheless, PCR
may improve the reliability of HCV diagnosis and is very
sensitive and specific in detecting viremia and therefore
potentially infectious blood donors (Sönmez et al. 1996,
Ginabreda et al. 1997, Gonçales et al. 2000). We found a
correlation between the presence of serum HCV RNA and
anti-HCV positivity (p < 0.05). However, among individu-
als with the ratio OD/C < 3 on ELISA and classified as
indeterminate or negative by the supplementary immu-
noblot assay, HCV RNA was identified in 44% of the
sample. Immunoblot indeterminate results were generally
(70%) associated with PCR positivity, indicating the need
to screen these donors for HCV-RNA in peripheral blood.
These results suggest that anti-HCV assays are not sen-
sitive enough to screen all asymptomatic HCV carriers.
Two samples (3.5%) had a high OD/C ratio on ELISA
(> 3) and a positive result on the supplementary im-
munoblot, but were negative for HCV RNA. This may re-
flect very low levels of viremia or virus clearance, since a
proportion of individuals varying from 15 to 25%  do not
progress to chronic infection (Hoofnagle 2002).
Routine immunoassays, such as ELISA, proved to be
valuable in identifying potentially infectious donors ca-
pable of transmitting hepatitis C, mainly in individuals
with OD/C ratios > 3. We observed that, in most cases
(93.7%), this high anti-HCV ratio was associated with HCV-
RNA positivity by PCR. However, the screening of low-
risk populations such as blood donors can give a sub-
stantial number of anti-HCV false-positive results, mainly
when low ELISA optical densities are obtained (Martins
et al. 1994). We observed that 24.6% of the sera with OD/
C < 3 were negative by RT-PCR.
TABLE
Results of the reverse transcriptase nested polymerase chain
reaction (PCR) for hepatitis C virus (HCV) RNA, anti-HCV
enzyme-linked immunosorbent assay (ELISA) and
immunoblot serological assays
ELISA        Immunoblot positive (n = 29)
PCR positive PCR negative
OD/C > 3 27/29 (93.1%) 2/29 (6.9%)
OD/C < 3 0/29 0/29
       Immunoblot indeterminate (n = 10)
PCR positive PCR negative
OD/C > 3 1/10 (10%) 0/10
OD/C < 3 6/10 (60%) 3/10 (30%)
       Immunoblot negative (n = 18)
PCR positive PCR negative
OD/C > 3 2/18 (11%) 0/18
OD/C < 3 5/18 (27.8%) 11/18
(61.2%)
OD/C: optical density divided by the cut off value.
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Genotyping of HCV isolates has been shown to be of
clinical importance. Nucleotide sequencing analysis of a
selected part of the viral genome has been used to deter-
mine the genotype of HCV isolates (Ginabreda et al. 1997).
To limit the occurrence of false-negatives in the PCR as-
say, we used primers in the 5’UTR of the HCV genome,
which is over 98% conserved among different isolates
(Ginabreda et al. 1997). The usage of the 5’UTR sequenc-
ing for HCV subtyping is considered controversial, since
this is a very conserved region of the genome (Pawlotsky
2002). Generally, only genotypes are used for clinical de-
cision related to therapy as different subtypes from the
same genotype have few clinical consequences (Krug et
al. 1996, Pawlotsky 2002).
The highest prevalence of HCV genotype 1 (60.9%),
followed by genotype 3 (39.1%) in the Federal District
corroborates previous data from Brazil. In Bahia, North-
eastern Brazil, HCV genotype 1 is the most frequent one
(66.1%), followed by the genotype 3 (33.9%). In the South-
east Region, genotype 1 is also predominant (55%), fol-
lowed by genotypes 3 (37%), and 2 (8%) (Bassit et al.
1994, Krug et al. 1996, Martins et al. 1998, Busek & Oliveira
2003, Codes et al. 2003).
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